Greffex has a Zika vaccine ready for testing
Read the full response from Greffex CEO John R. Price here, including a summary of potential vaccines from companies around the world:
The Zika virus, transmitted by mosquitos, is garnering more and more attention as studies show new adverse affects of Zika virus disease. While infection in adults result in mild symptoms, new data are showing that Zika infection may result in an increase in babies born with neurological disorders.
Zika concerns are rising as temperatures increase and bring booming mosquito populations and the geographic potential for infection increases, as well as concerns for athletes and tourists at the Olympics this summer in Brazil.
Greffex has produced a Zika vaccine and is ready for immediate testing. Our vaccine is based on our highly successful GreVac© platform employed in the development of the Greffex Avian Flu and MERS Co-V vaccine candidates.
More information is available from the WHO Zika factsheet at http://www.who.int/mediacentre/factsheets/zika/en/